tarlatamab   Click here for help

GtoPdb Ligand ID: 12969

Synonyms: AMG 757 | AMG-757 | AMG757
Compound class: Antibody
Comment: Tarlatamab (AMG 757) is a bispecific T cell engager (BiTE®) type anti-Delta-like ligand 3 (DLL3) monoclonal antibody [4-5]. It co-engages DLL3 on cancer cells and CD3E on T cells to promote T cell-mediated tumor lysis. The rationale for investigating DLL3 as a cancer drug target is reviewed in [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Addeo A, Banna GL, Friedlaender A. (2023)
Tarlatamab: a potential new option for recurrent small cell lung cancer.
Transl Lung Cancer Res, 12 (7): 1628-1630. [PMID:37577302]
2. Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS et al.. (2023)
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med, 389 (22): 2063-2075. [PMID:37861218]
3. Cortinovis DL, Colonese F, Abbate MI, Sala L, Meazza Prina M, Cordani N, Sala E, Canova S. (2022)
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons.
Front Med (Lausanne), 9: 989405. [PMID:36530878]
4. Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S et al.. (2021)
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Clin Cancer Res, 27 (5): 1526-1537. [PMID:33203642]
5. Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N et al.. (2023)
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
J Clin Oncol, 41 (16): 2893-2903. [PMID:36689692]
6. Tang D, Kang R. (2023)
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic.
Transl Lung Cancer Res, 12 (6): 1355-1357. [PMID:37425422]